Compare · DXCM vs KIDS
DXCM vs KIDS
Side-by-side comparison of DexCom Inc. (DXCM) and OrthoPediatrics Corp. (KIDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and KIDS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $27.61B, about 57.0x KIDS ($484.7M).
- Over the past year, DXCM is down 17.9% and KIDS is down 11.2% - KIDS leads by 6.7 points.
- DXCM has been more active in the news (6 items in the past 4 weeks vs 2 for KIDS).
- DXCM has more recent analyst coverage (25 ratings vs 8 for KIDS).
- Company
- DexCom Inc.
- OrthoPediatrics Corp.
- Price
- $73.54+2.80%
- $19.79+4.49%
- Market cap
- $27.61B
- $484.7M
- 1M return
- +7.17%
- +0.74%
- 1Y return
- -17.86%
- -11.20%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2017
- News (4w)
- 6
- 2
- Recent ratings
- 25
- 8
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Latest DXCM
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
Latest KIDS
- OrthoPediatrics Corp. to Report Second Quarter Financial Results on August 4, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by OrthoPediatrics Corp.
- OrthoPediatrics Announces Distribution Agreement with OSSIO, Inc. to Provide Revolutionary Orthopedic Fixation Technology to U.S. Children’s Hospitals Nationwide
- Director Pelizzon David R was granted 11,436 shares, increasing direct ownership by 35% to 44,384 units (SEC Form 4)
- Director Fischer Kelly Laine was granted 11,436 shares, increasing direct ownership by 263% to 15,781 units (SEC Form 4)
- Director Ruf Harold was granted 11,436 shares, increasing direct ownership by 136% to 19,837 units (SEC Form 4)
- Director Hughes Bryan W was granted 11,436 shares, increasing direct ownership by 54% to 32,663 units (SEC Form 4)
- Director Riccitelli Samuel D was granted 11,436 shares, increasing direct ownership by 56% to 31,859 units (SEC Form 4)
- Director Dyer George Sinclair Mitchell was granted 11,436 shares, increasing direct ownership by 87% to 24,568 units (SEC Form 4)
- Director Mcdonald Jimmy Duane was granted 11,436 shares, increasing direct ownership by 87% to 24,568 units (SEC Form 4)